Multiple mechanisms for the action of chymase inhibitors

Journal of Pharmacological Sciences

Volumn 118, Issue 3, 2012, Pages 311-316

  Takai, Shinji ^a   Jin, Denan ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin II; Chymase; Inhibitor; Matrix metalloproteianase 9; Transforming growth factor

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN II ANTAGONIST; CHYMASE; CHYMASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE B; GLUCOSE; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG EFFICACY; ENTERITIS; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INFLAMMATION; INFLAMMATORY CELL; ISCHEMIC HEART DISEASE; KIDNEY INJURY; LIVER FIBROSIS; MAST CELL; NONALCOHOLIC FATTY LIVER; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PLASMA RENIN ACTIVITY; REVIEW; TISSUE ADHESION; VASCULAR ENDOTHELIUM;

EID: 84859510328     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11R11CP     Document Type: Review

References (30)

1. Takai S, Sakaguchi M, Jin D, Yamada M, Kirimura K, Miyazaki M. Different angiotensin II-forming pathways in human and rat vascular tissues. Clin Chim Acta. 2001;305:191-195. (Pubitemid 32201977)
2. Takai S, Jin D, Miyazaki M. New approaches to blockade of the renin-angiotensin-aldosterone system: chymase as an important target to prevent organ damage. J Pharmacol Sci. 2010;113: 301-309.
3. Oyamada S, Bianchi C, Takai S, Chu LM, Sellke FW. Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion. J Pharmacol Exp Ther. 2011;339: 143-151.
4. Inoue N, Muramatsu M, Jin D, Takai S, Hayashi T, Katayama H, et al. Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice. Atherosclerosis. 2009;204:359-364.
5. Powell JS, Clozel JP, Müller RK, Kuhn H, Hefti F, Hosang M, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245: 186-188. (Pubitemid 19193936)
6. Kauffman RF, Bean JS, Zimmerman KM, Brown RF, Steinberg MI. Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. Life Sci. 1991;49:PL223-PL228.
7. Miyazaki M, Wada T, Shiota N, Takai S. Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury. J Hum Hypertens. 1999; 3 Suppl 1:S21-S25. (Pubitemid 29057651)
8. Takai S, Sakonjo H, Fukuda K, Jin D, Sakaguchi M, Kamoshita K, et al. A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine- 1-yl)-N-[[,4-dioxo-1-phenyl-7-(2-pyridyloxy)]2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury. J Pharmacol Exp Ther. 2003;304:841-844. (Pubitemid 36152364)
9. MERCATOR Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Circulation. 1992;86:100-110.
10. Peters S, Gotting B, Trummel M, Rust H, Brattstrom A. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol. 2001;13:93-97. (Pubitemid 33761992)
11. Jin D, Takai S, Shiota N, Miyazaki M. Roles of vascular angiotensin converting enzyme and chymase in two-kidney, one clip hypertensive hamsters. J Hypertens. 1998;16:657-664. (Pubitemid 28230554)
12. Kaartinen M, van der Wal AC, van der Loos CM, Piek JJ, Koch KT, Becker AE, et al. Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. J Am Coll Cardiol. 1998;32:606-612. (Pubitemid 28445520)
13. Furubayashi K, Takai S, Jin D, Miyazaki M, Katsumata T, Inagaki S, et al. Chymase activates promatrix metalloproteinase-9 in human abdominal aortic aneurysm. Clin Chim Acta. 2008; 388:214-216. (Pubitemid 350266567)
14. Jin D, Takai S, Yamada M, Sakaguchi M, Kamoshita K, Ishida K, et al. Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res. 2003;60: 413-420. (Pubitemid 37412375)
15. Jin D, Takai S, Yamada M, Sakaguchi M, Miyazaki M. Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction. Life Sci. 2002;71:437-446. (Pubitemid 34607306)
16. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106: 55-62. (Pubitemid 30437240)
17. Kanemitsu H, Takai S, Tsuneyoshi H, Nishina T, Yoshikawa K, Miyazaki M, et al. Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. Hypertens Res. 2006;29:57-64.
18. Manning MW, Cassis LA, Huang J, Szilvassy SJ, Daugherty A. Abdominal aortic aneurysms: fresh insights from a novel animal model of the disease. Vasc Med. 2002;7:45-54. (Pubitemid 34654073)
19. Chen J, Kuhlencordt PJ, Astern J, Gyurko R, Huang PL. Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. Circulation. 2001; 104:2391-2394. (Pubitemid 33108369)
20. Nishimoto M, Takai S, Fukumoto H, Tsunemi K, Yuda A, Sawada Y, et al. Increased local angiotensin II formation in aneurysmal aorta. Life Sci. 2002;71:2195-2205.
21. Takai S, Jin D, Miyazaki M. Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ. J Pharmacol Sci. 2011;116:309-315.
22. Takai S, Jin D, Ohzu M, Tanaka K, Miyazaki M. Chymase inhibition provides pancreatic islet protection in hamsters with streptozotocin-induced diabetes. J Pharmacol Sci. 2009;110: 459-465.
23. Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol. 2003;14:1816-1824. (Pubitemid 36750476)
24. Tani K, Ogushi F, Kido H, Kawano T, Kunori Y, Kamimura T, et al. Chymase is a potent chemoattractant for human monocytes and neutrophils. J Leukoc Biol. 2000;67:585-589.
25. Tashiro K, Takai S, Jin D, Yamamoto H, Komeda K, Hayashi M, et al. Chymase inhibitor prevents the nonalcoholic steatohepatitis in hamsters fed a methionine- and choline-deficient diet. Hepatol Res. 2010;40:832-840.
26. Castaneda FE, Walia B, Vijay-Kumar M, Patel NR, Roser S, Kolachala VL, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology. 2005;129:1991-2008. (Pubitemid 41772976)
27. Kakimoto K, Takai S, Murano M, Ishida K, Yoda Y, Inoue T, et al. Significance of chymase-dependent matrix metalloproteinase-9 activation on indomethacin-induced small intestinal damages in rats. J Pharmacol Exp Ther. 2010;332:684-689.
28. Lucas PA, Warejcka DJ, Young HE, Lee BY. Formation of abdominal adhesions is inhibited by antibodies to transforming growth factor-β1. J Surg Res. 1996;65:135-138. (Pubitemid 26367581)
29. Okamoto Y, Takai S, Miyazaki M. Chymase inhibitor, BCEAB, suppressed peritoneal adhesion formation in hamster. J Surg Res. 2002;107:219-222. (Pubitemid 35379662)
30. Okamoto Y, Takai S, Miyazaki M. Effect of chymase-dependent transforming growth factor beta on peritoneal adhesion formation in a rat model. Surg Today. 2004;34:865-867. (Pubitemid 39331210)